The present disclosure relates generally to pharmaceutical formulations ofLafutidine. More specifically, the disclosure is directed to a microemulsionformulation for management of gastric ulcer comprising Lafutidine, an oil phaseof virgin coconut oil, a surfactant and a co-surfactant.
